Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel

Launched by CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY CO., LTD. · Jul 14, 2020

Keywords

ClinConnect Summary

This study was conducted in two stages. The first stage (Stage I) is a dose-escalation study. A classic 3+3 design will be used to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D). Patients with advanced solid tumors will be assigned to receive sequentially higher doses of albumin-bound formulation of docetaxel once every three weeks (a Cycle) by intravenous infusion, starting at a dose of 50mg/m2. Patients will receive the albumin-bound formulation of docetaxel

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18, ≤75 years, no gender limitation；
• • 2. Histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumors, for which standard therapy either does not exist or has proven to be ineffective, intolerable or unacceptable for the patient；
• • 3. At least one measurable lesion as per RECIST version 1.1；
• • 4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1；
• • 5. Life expectancy ≥3 months；
• • 6. Adequate bone marrow, cardiac, liver and renal function；
• Exclusion Criteria:
• • 1. Chemotherapy, radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy and other anti-tumor treatment within 4 weeks of the first dose of the study drug, 6 weeks for mitomycin C or nitrosoureas, 2 weeks (or 5 half-lives whichever is longer) for using fluorouracil or small molecule targeted drugs, 2 weeks for using traditional Chinese medicine with anti-tumor indications；
• • 2. Currently enrolled in any other clinical study, or administration of other investigational agents w